Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

by Erin Jensen, Evan J Lipson, Martin A Cheever, Adil Daud, Brent A Hanks, Shailender Bhatia, Thomas Olencki, Kari Kendra, Mizuho Kalabis, William H Sharfman, Ragini R Kudchadkar, Philip A Friedlander, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Candice Church, Tomoko Akaike, Michi M Shinohara, Bob Salim, Blanca Homet Moreno
Published 2021-04-01